IV DRESSING WITH EMBEDDED SENSORS FOR MEASURING FLUID INFILTRATION AND PHYSIOLOGICAL PARAMETERS
20220095940 · 2022-03-31
Inventors
- Matthew Banet (Deerfield, IL, US)
- Mark Dhillon (Deerfield, IL, US)
- Erik Tang (Deerfield, IL, US)
- Marshal Dhillon (Deerfield, IL, US)
- James McCanna (Deerfield, IL, US)
- Chethanya Eleswarpu (Deerfield, IL, US)
- James P. Martucci (Deerfield, IL, US)
- Matthew A. Bivans (Deerfield, IL, US)
- Justin Buckingham (Deerfield, IL, US)
- Ahren Ceisel (Deerfield, IL, US)
- Michael Needham (Deerfield, IL, US)
- Lauren Hayward (Deerfield, IL, US)
Cpc classification
A61B5/11
HUMAN NECESSITIES
A61B5/02141
HUMAN NECESSITIES
A61B5/0205
HUMAN NECESSITIES
A61B2562/0219
HUMAN NECESSITIES
A61B5/725
HUMAN NECESSITIES
International classification
A61B5/00
HUMAN NECESSITIES
Abstract
The invention provides an intravenous (IV) dressing system that helps secure an IV catheter to a patient while simultaneously using embedded peripheral venous pressure (PVP), impedance, temperature, optical, and motion sensors to characterize properties of the IV system (e.g., infiltration, extravasation, occlusion) and the patient's physiological parameters (e.g., heart rate, SpO2, respiration rate, temperature, and blood pressure). Notably, the system converts PVP waveforms into arterial BP values (e.g., systolic and diastolic blood pressure).
Claims
1. A system for determining an arterial blood pressure value from a patient, comprising: a catheter configured to insert into the patient's venous system; a pressure sensor connected to the catheter and configured to measure physiological signals indicating a pressure in the patient's venous system; and a processing system configured to: i) receive the physiological signals from the pressure sensor; and ii) process the physiological signals with an algorithm to determine the arterial blood pressure value.
2. The system of claim 1, wherein the processing system is further configured to operate an algorithm that filters out respiratory components from the physiological signals to determine the arterial blood pressure value.
3. The system of claim 2, wherein the algorithm is further configured to operate a bandpass filter to filter out respiratory components from the physiological signals.
4. The system of claim 2, wherein the algorithm is further configured to operate a filter based on wavelets to filter out respiratory components from the physiological signals.
5. The system of claim 1, wherein the processing system is enclosed by an enclosure that is configured to attach directly to the patient.
6. The system of claim 1, wherein the processing system further comprises a motion-detecting sensor.
7. The system of claim 6, wherein the motion-detecting sensor is one of an accelerometer and a gyroscope.
8. The system of claim 6, wherein the processing system is further configured to receive signals from the motion-detecting sensor and process them to determine the patient's degree of motion.
9. The system of claim 8, wherein the processing system is further configured to collectively process the patient's degree of motion and the physiological signals to determine the arterial blood pressure value.
10. The system of claim 6, wherein the processing system is further configured to receive signals from the motion-detecting sensor and process them to determine a relative height associated with a body part associated with the patient.
11. The system of claim 10, wherein the body part is the patient's arm.
12. The system of claim 10, wherein the processing system is further configured to collectively process the relative height associated with the body part associated with the patient and the physiological signals to determine the arterial blood pressure value.
13. The system of claim 1, wherein the processing system is further configured to receive a calibration blood pressure value from an external source.
14. The system of claim 13, wherein the processing system is further configured to process the calibration blood pressure value with the physiological signals to determine the arterial blood pressure value.
15. The system of claim 14, wherein the external source is one of a blood pressure cuff and an arterial catheter.
16. The system of claim 14, wherein the processing system is further configured to process a patient-specific relationship between venous blood pressure and arterial blood pressure, along with the calibration blood pressure value and the physiological signals, to determine the arterial blood pressure value.
17. The system of claim 16, wherein the processing system is further configured to process the physiological signals to determine the patient-specific relationship between venous blood pressure and arterial blood pressure.
18. The system of claim 16, wherein the processing system is further configured to process biometric information corresponding to the patient to determine the patient-specific relationship between venous blood pressure and arterial blood pressure.
19. A system for determining an arterial blood pressure value from a patient, comprising: a catheter configured to insert into the patient's venous system; a pressure sensor connected to the catheter and configured to measure physiological signals indicating a pressure in the patient's venous system; a motion sensor configured to measure motion signals; and, a processing system configured to: i) receive the physiological signals from the pressure sensor; ii) receive the motion signals from the motion sensor; iii) process the motion signals by comparing them to a pre-determined threshold value to determine when the patient has a relatively low degree of motion; and iv) process the physiological signals to determine the arterial blood pressure value.
20. A system for determining an arterial blood pressure value from a patient, comprising: a catheter configured to insert into the patient's venous system; a pressure sensor connected to the catheter and configured to measure physiological signals indicating a pressure in the patient's venous system; a motion sensor configured to measure motion signals; and, a processing system configured to: i) receive the physiological signals from the pressure sensor; ii) receive the motion signals from the motion sensor; iii) process the motion signals to determine a relative height between a body part associated with the patient and an infusion system; and iv) process the physiological signals and the relative height to determine the arterial blood pressure value.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0126]
[0127]
[0128]
[0129]
[0130]
[0131]
[0132]
[0133]
[0134]
[0135]
[0136]
[0137]
[0138]
[0139]
[0140]
[0141]
[0142]
[0143]
[0144]
[0145]
[0146]
[0147]
[0148]
[0149]
[0150]
[0151]
[0152]
[0153]
[0154]
[0155]
[0156]
[0157]
DETAILED DESCRIPTION
1. Overview
[0158] Although the following text sets forth a detailed description of numerous different embodiments, it should be understood that the legal scope of the invention described herein is defined by the words of the claims set forth at the end of this patent. The detailed description is to be construed as exemplary only; it does not describe every possible embodiment, as this would be impractical, if not impossible. One of ordinary skill in the art could implement numerous alternate embodiments, which would still fall within the scope of the claims.
2. IVDS
[0159] Referring to
[0160] The IVDS features a flexible, breathable polymeric base 89—similar that used in a large bandage—with a biocompatible adhesive on one side that secures the IV catheter 21 in place. In
[0161] During use, the set of electrodes 83 attach to the patient's skin to measure bio-electric signals that, once processed with the electronics module 94, indicate the electrical impedance of tissue disposed underneath the polymeric base 89. The polymeric base 89 additionally includes a temperature sensor 85 that connects through a second set of electrical traces 86 to the cable 88, which ports electrical signals from the electrodes 83 and temperature sensor 85 to the first connector 91. The first connector 91 mates with a second connector 92 that ports the electrical signals to the electronics module 94 within the arm-worn housing 20. Typically, the second connector 92, electronics module 94, and arm-worn housing are considered ‘reusable’ components of the IVDS, whereas the other components shown in
[0162] During use, the catheter 21 inserts into the patient's vein and connects to an infusion pump (not shown in the figure but indicated in
[0163]
[0164] As indicated in the graph, infiltration was initiated at approximately 60 seconds. Fluctuations in the motion waveform indicate that, at this time, the patient moved, thereby causing the catheter 21 to push from within a vein 124 in the arm-worn rig into the surrounding tissue 122, which is typically composed of agar, a conductive, gelatinous material. The arm-worn rig additionally includes synthetic components representing a bone 126 and skin 120. Additionally, a control circuit and motorized pump (not shown in the figure) attaches to the vein and pumps a conductive, blood-like liquid at a ‘heart rate’ that is approximately 60 beats/min.
[0165] Referring to
[0166] As shown in the graph in
[0167] A similar situation exists for the temperature waveform, as shown in the graph in
[0168] The PVP waveform is measured with a pressure sensor configured as shown in
[0169] Several things happen to the PVP waveform after infiltration. Referring specifically to
[0170] In summary, within the PVP waveform there are several signal components—rapid rise in pressure, heartbeat-induced pulses and their subsequent disappearance, large pressure pulses—that an algorithm can process to characterize IV infiltration. Such an algorithm can collectively process PVP waveforms along with IMP, temperature, and motion waveforms to better detect this event. Additionally, other sensors, such as those that measure optical, acoustic, bio-reactance, and other waveforms, can be added to the IVDS to better detect this event.
[0171] Additional algorithms can also process the PVP waveform, which represents a venous pressure, to determine arterial blood pressure, as indicated by
[0172]
[0173] The IV system 19 features a bag 16 containing pharmaceutical compounds and/or fluid (herein “medication” 17) for the patient. The bag 16 connects to an infusion pump 12 through a first tube 14. A standard IV pole 28 supports the bag 16, the infusion pump 12, and the remote processor 36. A display 13 on the front panel of the infusion pump 12 indicates the type of medication delivered to the patient, its flow rate, measurement time, etc. Medication 17 passes from the bag 16 through the first tube 14 and into the infusion pump 12. From there, it is metered out appropriately, and passes through a second tube 18, through the connector 91 featuring a pressure sensor, and finally through the venous catheter 21 and into the patient's venous system 23. The arm-worn housing 20 connects to the connector 91 and is typically affixed to the patient's arm or hand, e.g., using an adhesive such as medical tape or a disposable electrode.
[0174] The venous catheter 21 may be a standard venous access device, and thus may include a needle, catheter, cannula, or other means of establishing a fluid connection between the catheter 21 and the patient's peripheral venous system 23. The venous access device may be a separate component connected to the venous catheter 21, or may be formed as an integral portion of it. In this way, the IV system 19 supplies the medication 17 to the patient's venous system 23 while the IVDS 80, which features a pressure-measuring system and described in more detailed below, simultaneously measures signals related to the patient's PVP and vital signs.
[0175] Importantly, and as described in more detail below, the IVDS 80 is designed so that it is in constant ‘fluid connection’ with the patient's circulatory system (and particularly the venous system) while being deployed close to (or directly on) the patient's body. It features electronic systems for measuring analog pressure signals within the patient's venous system to generate PVP waveforms, and then amplifying and filtering these to optimize their signal-to-noise ratios. An analog-to-digital converter within the arm-worn housing digitizes the analog PVP waveforms prior to transmitting them through the cable, thereby minimizing any noise (caused, e.g., by the cable's motion) that would normally affect transmitted analog signals and ultimately introduce inaccuracies into values (e.g., values of BP, HR, RR, F0 and F1) measured downstream. Notably, this design provides a relatively short conduction path between where the PVP waveforms are first detected and then processed and digitized; ultimately this results in signals that are more likely to yield highly accurate values of wedge pressure (and in embodiments pulmonary arterial pressure, and particularly the diastolic component on this pressure, blood volume and other fluid-related parameters).
[0176]
3. PVP-Conditioning Circuit Board
[0177]
[0178] The PVP-conditioning circuit board 62 additionally includes sets of metal-plated holes that support a 4-pin connector 69, two 6-pin connectors 77, 78, and a 3-pin connector 79. More specifically, connector 69 connects directly to the pressure transducer, where it receives a common ground signal and analog PVP waveforms representing pressure in the patient's venous system. These waveforms are filtered and digitized as described in more detail, below. Through the connector 79 the circuit board receives power (+5V, +3.3V, and ground) from an external power supply, e.g., a battery or power supply located in the arm-worn housing. These power levels may be different in other embodiments of the invention. Digital signals and a corresponding ground from the analog-to-digital converter 68 are terminated at connector 78; they leave the circuit board 62 at this point, e.g., through cable segment 37 shown in
[0179] The PVP-conditioning circuit board 62 typically connects to the electronics module through a serial interface (e.g., SPI, I2C), which includes components for processing, storing, and transmitting data that are digitized by the analog-to-digital converter 68. For example, electronics module typically includes a microprocessor, microcontroller, or similar integrated circuit, and can additionally provide analog and digital circuitry for the IVDS. In embodiments, the microprocessor or microcontroller thereon can operate computer code to process PVP-AC, PVP-DC, PPG, IMP, BP, and other time-dependent waveforms to determine vital signs (e.g., HR, HRV, RR, BP, SpO2, TEMP), hemodynamic parameters (CO, SV, FLUIDS), components of PVP waveforms (e.g., F0, F1, and amplitudes and energies associated thereto), and associated parameters (e.g., wedge pressure, central venous pressure, blood volume, fluid volume, and pulmonary arterial pressure) related to the patient's fluid status. “Processing” by the microprocessor in this way, as used herein, means using computer code or a comparable approach to digitally filter (e.g., with a high-pass, low-pass, and/or band-pass filter), transform (e.g., using FFT, CWTs, and/or DWTs), mathematically manipulate, and generally process and analyze the waveforms and parameters and constructs derived therefrom with algorithms known in the art. Examples of such algorithms include those described in the following co-pending and issued patents, the contents of which are incorporated herein by reference: “NECK-WORN PHYSIOLOGICAL MONITOR”, U.S. Ser. No. 14/975,646, filed Dec. 18, 2015; “NECKLACE-SHAPED PHYSIOLOGICAL MONITOR”, U.S. Ser. No. 14/184,616, filed Aug. 21, 2014; and “BODY-WORN SENSOR FOR CHARACTERIZING PATIENTS WITH HEART FAILURE”, U.S. Ser. No. 14/145,253, filed Jul. 3, 2014.
[0180] In related embodiments, the electronics module can include both flash memory and random-access memory for storing time-dependent waveforms and numerical values, either before or after processing by the microprocessor. In still other embodiments, the circuit board can include Bluetooth® and/or Wi-Fi transceivers for both transmitting and receiving information.
[0181] PVP waveforms measured with the system described herein feature signal components that relate to heartbeat and respiratory events that may vary rapidly with time.
[0182] More specifically, PVP waveforms typically have signal levels in the 5-50 □V range, a relatively weak amplitude that can be difficult to process. Such signals have been described previously, e.g., in U.S. patent application Ser. No. 16/023,945 (filed Jun. 29, 2018 and published as U.S. Patent Publication 2019/0000326); U.S. patent application Ser. No. 14/853,504 (filed Sep. 14, 2015 and published as U.S. Patent Publication No. 2016/0073959), and PCT Application No. PCT/US16/16420 (filed Feb. 3, 2016 and published as WO 2016/126856). The contents of these pending patent applications are incorporated herein by reference. During a measurement, as described in these documents, a pressure sensor proximal to the patient measures the PVP waveform and generates corresponding analog signals; these typically pass through a relatively long cable, and are amplified, filtered, and digitized with a system located remotely from the patient. However, because PVP waveforms are so weak and characterized by low signal-to-noise ratios, they can be extremely difficult to measure. It is therefore advantageous to digitize these signals before they propagate through a long, ‘lossy’ cable.
[0183]
[0184] More specifically, the circuit described by the schematic 100 is designed to serially perform the following function on incoming PVP waveforms:
[0185] Incoming PVP Waveforms
[0186] 1) Amplify the signal with 100× gain using a zero-drift amplifier
[0187] 2) Differentially amplify the signal with an additional 10× gain
[0188] 3) Filter the amplified signals with a 25 Hz, 2-pole low-pass filter
[0189] This first portion of the circuit provides roughly 1000× combined gain for the incoming PVP waveforms, thereby amplifying the input signal (which is typically in the □V range) to a larger signal (in the mV range). The follow-on low-pass filter removes any high-frequency noise. Ultimately these steps facilitate processing of both the PVP-AC and PVP-DC waveforms, as described below.
[0190] In the descriptions provided herein, the term ‘differentially amplify’ refers to a process wherein the circuit measures the difference between positive (P_IN in
[0191] Likewise, the term ‘zero-drift amplifier’ refers to an amplifier that: 1) internally corrects for temperature and other forms of low-frequency signal error; 2) has very high input impedance; and 3) has very low offset voltages. The incoming signal received by a zero-drift amplifier is typically extremely small, meaning it can be subject to interference, gain shifts, or the amplifier inputs bleeding out generated current; the zero-drift architecture of the amplifier helps reduce or eliminate this.
[0192] After processing the input PVP waveforms, the circuit described by the schematic 100 is designed to serially perform the following function on PVP-AC and PVP-DC waveforms:
[0193] PVP-AC Waveforms Only [0194] 1) Filter the signal with a 0.1 Hz, 2-pole high-pass filter [0195] 2) Filter the signal with a 15 Hz, 2-pole low-pass filter [0196] 3) Amplify the signal with 50× gain
[0197] PVP-DC Signal Only [0198] 1) Filter the signal with a 0.07 Hz, 2-pole low-pass filter [0199] 2) Filter the signal with a 0.13 Hz, 2-pole low-pass filter [0200] 3) Amplify the signal with 10× gain
[0201] Both PVP-AC and PVP-DC Waveforms [0202] 1) Digitize the signals with a 16-bit, 200 Ksps Delta-Sigma analog-to-digital converter
[0203] With this level of digital signal processing, the circuit board 62 can process PVP waveforms directly on the patient's body, and more specifically signals associated with IV infiltration, respiration rate and heart rate. It performs these functions without having to send signals through an external cable, which is an approach that can add noise and other signal artifacts and thus negatively impact measurement of these parameters.
[0204] As appreciated by those skilled in the art, the circuit elements 102, 104, and 106 shown in
[0205] Alternatively, a motion signal measured by one of these components can be processed and compared to a pre-existing threshold value: if the signal exceeds the pre-determined threshold value, it can indicate that the patient is moving too much to make an accurate measurement; if the signal is less than the pre-determined threshold value, it can indicate that the patient is stable and that an accurate measurement can be made.
[0206] Such circuit elements 102, 104, and 106 are typically fabricated on a small, fiberglass circuit board, such as that shown in
[0207]
[0208] Importantly and as described above, the analog signal processing indicated in
4. Blood Pressure Measurement
[0209] Even after being processing with the PVP-conditioning circuit board, PVP waveforms measured can feature low-signal to noise ratios, thereby making it difficult to extract individual heartbeat-induced pulses that are required to estimate arterial BP using the algorithm described herein. Referring to
[0210]
[0211] Ideally, because of the typical low signal-to-noise ratio of PVP waveforms, the IVDS described herein uses the IVDS beatpicking algorithm as described in the above-mentioned reference and demonstrated with the data shown in
[0212]
[0216] With regard to Point 1, the graphs in
[0217] With regard to Points 2 and 3, comparison of the graphs shown in
[0218]
[0219] Data in these figures corroborate the three ‘Points’ made above: in all cases, the IVDS beatpicking algorithm is effective in locating cardiac pulses, particularly in the relatively challenging PVP waveforms. There is strong correlation between changes in the arterial BP and PVP waveforms. Moreover, in all cases, the two waveforms are both modulated by the subject's respiration in a consistent manner, with the modulation being significantly more pronounced and resulting in relatively large changes in the PVP waveforms. Importantly, the agreement between the two waveforms persists even during periods where respiratory-induced modulation is not present. For example, in
[0220] Without being bound to any particular theory, the relatively large modulation present in PVP waveforms as compared to arterial BP waveforms, as indicated by
[0221] There is no single compliance curve for a blood vessel. For example, as shown in
[0222] Compliance as described above represents the static compliance generated by expanding a vessel by a known volume and measuring the change in pressure at steady-state. Typically, the compliance of a vessel (either artery or vein) is also dependent upon the rate by which the change in volume occurs, i.e., there is a dynamic component to compliance. This is indicated in
[0223] When respiratory-induced modulation of both the arterial BP and PVP waveforms is removed, e.g., using a digital filtering technique, the agreement between the two signals is increased. For example,
[0224] Both
[0225] In embodiments, the filter used to remove respiration components can be something other than a bandpass filter. Other candidate filters include a filter based on wavelets (e.g., CWT or DWT), an adaptive filter wherein respiration is measured with another technique (e.g., from the IMP waveform) and then used within a separate filter for PVP waveforms, a filter based in the frequency domain (e.g., one that is applied after the time-domain waveform is converted into a frequency-domain waveform using an FFT), or a simple smoothing algorithm. Other comparable digital filtering or digital signal-processing techniques for removing or reducing signal artifacts due to respiration modulation are within the scope of the invention.
[0226] Beatpicks from PVP waveforms correspond to systolic pressure within the vein, and typically have pressure values in the range of 10-30 mmHg, whereas those from arterial BP correspond directly to SYS and are relatively higher, e.g., typically in the range of 70-150 mmHg. Moreover, there does not appear to be universal relationship between venous and arterial pressures that applies to all patients. This means that, in order to estimate arterial BP from PVP waveforms, a calibration must be performed.
[0227] Referring to
[0228] To initiate a measurement, a clinician (or the actual patient 11) presses an on/off button 184 on the blood pressure cuff 181. This activates the pump within the control module 182, causing it to inflate the bladder within the cuff, collect pressure signals from the patient's bicep, and generally perform a standard blood pressure measurement using oscillometry. This yields initial values of SYS, DIA, and MAP. Additionally, the pressure sensor within the blood pressure cuff 181 measures a time-dependent pressure waveform that indicates the pressure applied to the patient's brachial artery by the flexible cuff 180. Once measured, these parameters—values of SYS, DIA, and MAP, along with a time-dependent pressure waveform—are wirelessly transmitted by the Bluetooth® transceiver within the blood pressure cuff 181 to a paired Bluetooth® transceiver within the electronics module 94 enclosed by the arm-worn housing 20. More specifically, the microprocessor featured in the electronics module 94 receives and processes these parameters, along with other time-dependent waveforms measured by the IVDS 80, to determine a patient-specific calibration, as described in more detail below.
[0229] The Bluetooth® communication between the blood pressure cuff 181 and the electronics module 94 in the IVDS 80, as indicated by the arrow 188 in the figure, is a two-way connection: as described above, the blood pressure cuff 181 sends values of SYS, DIA, and MAP and a time-dependent pressure waveform to the IVDS 80, and this system processes this information to generate a patient-specific calibration, and can also send information (such as an acknowledgement, error code, or instruction to initiate a new calibration measurement) to the blood pressure cuff 181.
[0230] The patient-specific calibration is typically determined by collectively analyzing the time-dependent pressure waveform from the blood pressure cuff 181, along with time-dependent waveforms collected by the IVDS 80, e.g., IMP, temperature, PPG, and motion waveforms, and time-dependent PVP-AC and PVP-DC waveforms measured by the PVP-conditioning circuit board 95. Similar techniques have been described in the following U.S. Patents, the contents of which are incorporated herein by reference: Banet et al., Body-worn system for continuous, noninvasive measurement of cardiac output, stroke volume, cardiac power, and blood pressure, U.S. Pat. No. 10,722,131; Banet et al., Handheld physiological sensor, U.S. Pat. No. 10,206,600; McCombie et al., System for calibrating a PTT-based blood pressure measurement using arm height, U.S. Pat. No. 8,672,854; Banet et al., Cuffless system for measuring blood pressure, 7,179,228; and Banet et al., Blood-pressure monitoring device featuring a calibration-based analysis, 7,004,907.
[0231] More specifically, to determine the patient-specific calibration, Multiple values of PVP values and arterial BP values can be collected and analyzed to determine patient-specific slopes, which relate changes in PVP with changes in SYS, DIA, and MAP. The patient-specific slopes can also be determined using pre-determined values from a clinical study, and then combining these measurements with biometric parameters (e.g., age, gender, height, weight) collected during the clinical study. In still other embodiments, the patient-specific slope can be determined by detecting the change in PVP (as measured with the PVP-conditioning circuit board 95) with the change in applied pressure to the brachium (as measured with the control module 182 within the blood pressure cuff 181). Here, arterial pressure can be estimated from the variable pressure applied by the blood pressure cuff 181, and then correlated with the variably PVP measured during inflation of the cuff. This relationship can then be used to estimate the patient-specific calibration. Other calibration approaches, such as empirical methods based on the patient's biometric parameters, and as described in the above-mentioned patents, are also within the scope of the invention.
[0232] Once a measurement is complete, the IVDS 80 can wirelessly transmit numerical values through a Bluetooth® interface, as indicated by arrow 189, to an external display, such as an infusion pump 192. This type of communication, for example, allows for a closed-loop system wherein the infusion pump 192 delivers fluids to the patient to impact their BP, blood volume, and other physiological parameters, and the IVDS 80 determines whether or not the fluids are delivered to the patient's venous system or infiltrating into underlying tissue, and additionally how the patient is responding to the delivered fluids. In other embodiments, the IVDS 80 sends information through a similar wireless interface to another remote display, such as a mobile telephone, computer, tablet computer, television, hospital EMR, or another comparable display device.
[0233]
[0234] The change in PVP signals with arm height and the ability to automatically characterize the relative arm height with an accelerometer are important for several reasons. First, because both PVP and arterial BP change with a change in arm height in a continuous, well-defined manner, a process involving systematic variation of arm height may be used to calibrate a blood pressure measurement based on PVP, as described above. Second, because PVP signals (both baseline and heartbeat-induced pulses) vary with arm height, an accurate arterial BP measurement based on them will need to account for arm height, as measured with an accelerometer.
[0235] For the IVDS, calculating arm height from an accelerometer signal is preferably done by generating a series of look-up tables' beforehand that feature separate entries for both parameters, as characterized with a clinical trial involving subjects of varying demographics (e.g., height, weight, BMI, gender, age). The look-up tables are preferably coded into the IVDS's software during manufacturing. During an actual measurement, the accelerometer signals is measured and compared to the appropriate look-up table to estimate the arm height.
[0236] An algorithm based on the results shown in
[0237]
[0238]
5. Measurement of Motion and Posture with the IVDS
[0239] The same accelerometer used in the IVDS to estimate arm height can also detect a patient's motion and posture, e.g., during a hospital stay. And importantly, it can be used to characterize periods of motion that may make the measurements described herein—IV infiltration and PVP-based BP—difficult or impossible because of motion-related artifacts. In short, the accelerometer can detect motion, which by itself is useful for characterizing a patient, while additionally indicating periods when the patient is relatively motion-free and a measurement can ideally be made.
[0240]
[0241] In preferred embodiments, the microprocessor positioned on the IVDS's electronics module operates an algorithm that continuously processes signals from all 3 axes of the accelerometer. By comparing these data to that in a pre-determined look-up table, or alternatively first-principles models, the algorithm determines: 1) the type of motion the patient is undergoing; and 2) whether or not the motion is severe enough to impact the PVP-based blood pressure measurement, as well as measurements of other vital signs as described below. The IVDS reports a set of values when the motion is such that the algorithm determines that a measurement can be made.
[0242] In other embodiments, using information from the accelerometer, the IVDS can determine events that are about to occur, such as a patient moving around in a hospital bed and preparing to exit the bed. In these and other instances, the IVDS can wirelessly transmit an ‘alarm’ or an ‘alert’ to a remote display, e.g., an infusion pump as indicated in
6. Measurement of Other Vital Signs and Physiological Parameters with the IVDS
[0243] The same sensors described herein that are used to detect IV infiltration—most notably the IMP, temperature, and the PVP-conditioning circuit board used to process PVP signals—can perform ‘double duty’ and additionally measure waveforms that yield other vital signs, such as HR, HRV, RR, and TEMP. Additionally, the IVDS can include a reflective optical system (typically disposed within the flexible, breathable polymeric base (component 89) in
[0244] Electrodes (i.e., components 83 in
[0245] Physiological processes within a patient's arm modulate □Z(t) and Z0 waveforms sensed by the IVDS's bio-impedance measurement system. Thus processing these waveforms can yield parameters that correspond to the physiological processes. For example, respiratory effort (i.e., breathing), affect □Z(t) to impart a series of low-frequency undulations (typically 5-30 undulations/minute) on the waveform. The IVDS's electronics module processes these oscillations to determine RR. Blood is a good electrical conductor, and thus blood flow in the patient's arm manifests as heartbeat-induced cardiac pulses on the □Z(t) waveform. They can be processed with known techniques in the art to determine HR and HRV.
[0246] Physiological fluids in the arm also conduct the injected current. They can accumulate in this region (much like fluids accumulate to detect IV infiltration, albeit on a much slower time scale) and affect the impedance within the electrode's conduction pathway in a low-frequency (i.e., slowly changing) manner; processing the Z0 waveform can therefore detect them. Typically, the Z0 waveform features an average value of between about 10-50 Ohms, with 10 Ohms indicating relatively low impedance and thus high fluid content (e.g., the patient is ‘wet’), and 50 Ohms indicating a relatively high impedance and thus low fluid content (e.g., the patient is dry′). Time-dependent changes in the average value of Z0 can indicate that the patient's fluid level is either increasing or decreasing. An increase in fluid level, for example, may indicate the onset of congestive heart failure or kidney failure.
[0247] To measure optical signals, the IVDS may include a light source, e.g., a dual-emitting LED operating in a transmissive or reflective-mode geometry, which generates red and infrared optical wavelengths in the □=660 nm and □=908 nm region, and a photodetector (e.g., photodiode). These components measure PPG waveforms using both red and infrared radiation, as is generally known in the art, from either the patient's arm or one of their digits (e.g., the thumb) that is proximal to the IV site. The electronics module processes the waveforms to determine SpO2. Such measurement is described in more detail in the following co-pending patent applications, the contents of which are incorporated herein by reference: “NECK-WORN PHYSIOLOGICAL MONITOR”, U.S. Ser. No. 62/049,279, filed Sep. 11, 2014; “NECKLACE-SHAPED PHYSIOLOGICAL MONITOR”, U.S. Ser. No. 14/184,616, filed Feb. 19, 2014; and “BODY-WORN SENSOR FOR CHARACTERIZING PATIENTS WITH HEART FAILURE”, U.S. Ser. No. 14/145,253, filed Dec. 31, 2013. In general, and as explained in greater detail in these incorporated references, during an SpO2 measurement, the digital system alternately powers red and infrared LEDs within the dual-emitting LED. This process generates two distinct PPG waveforms. Using both digital and analog filters, the digital system extracts AC and DC components from the red (RED(AC) and RED(DC)) and infrared (IR(AC) and IR(DC)) PPG waveforms, which the digital system then processes to determine SpO2, as described in the above-referenced patent applications. To enhance the optical signal, the IVDS may include a thin film heating element, such as a Kapton® film with embedded electrical conductors arranged, e.g., in a serpentine pattern. Typically, the temperature of the heating element is regulated in a closed-loop manner at a level of between 41 to 42° C., which has minimal effect on the underlying tissue and is considered safe by the U.S. Food and Drug Administration (FDA).
[0248] Such an optical system and thin film heating element is described in the following patent application, the contents of which are incorporated herein by reference: “PATCH-BASED PHYSIOLOGICAL SENSOR” U.S. Ser. No. 16/044,386, filed Jul. 24, 2018.
[0249]
[0250] Likewise, the optical sensor in the IVDS measured PPG waveforms using both RED an IR radiation. Typically, the waveform measured with IR radiation had a relatively high signal-to-noise ratio. From the PPG waveforms PR and SpO2 values were calculated, as described above. As with the above-described electrodes, the optical system used for these measurements is that same as that used to detect IV infiltration, as described above.
[0251] Additionally, the PVP waveform can be processed to determine HR, RR, and other hemodynamic parameters. These measurements can be used to offset or improve those made with IMP and PPG waveforms, as described with reference to
[0256] In other embodiments, the IVDS may collectively process hemodynamic parameters measured PVP waveform (e.g., wedge pressure and blood volume, which may be correlates with energies associated with F0, F1, or some combination thereof) with those measured by other sensors within the IVDS (e.g., BP, SpO2) to determine the patient's fluid status and effectively inform delivery of fluids while resuscitating the patient (e.g., during periods of sepsis and/or fluid overload). In general, by using information from both the PVP waveform and IVDS, a clinician can better manage the patient 11 by characterizing life-threatening conditions and help guide their resuscitation.
[0257] As a more specific example, in embodiments values of BP and SpO2 measured by the IVDS can be combined with volume status determined from the PVP waveform to estimate a patient's blood flow and perfusion. Knowledge of these parameters, in turn, can inform estimation of how much fluid a clinician needs to deliver upon resuscitation. Similarly, BP, and SpO2 measured by the IVDS, along with the ratio of F0 and F1 energies measured from the PVP waveform, each indicate a patient's level of perfusion. They can also be combined in a mathematical ‘index’ to better estimate this condition. Then these parameters or the index can be measured while the patient undergoes a technique called a ‘passive leg raise’, which is a test to evaluate the need for further fluid resuscitation in a critically ill person. The passive leg raise involves raising a patient's legs (typically without their active participation), which causes gravity to pull blood from the legs into the central organs, thereby increasing circulatory volume available to the heart (typically called ‘cardiac preload’) by around 150-300 milliliters, depending on the amount of venous reservoir. If the above-mentioned parameters or index measured by the IVDS increase, this can indicate that the leg raise effectively increases perfusion in the patient's central organs, thereby indicating that they will be responsive to fluids. Clinicians can perform a similar test by providing the patient a bolus of fluids through an IV system, and then monitoring the increase or decrease in the parameters or index measured by the IVDS.
[0258] In embodiments, simple linear computational methods, combined with results from clinical studies, can be used to develop models that collectively process data generated by the IVDS. In other embodiments, more sophisticated computational models, such as those involving artificial intelligence and/or machine learning, can be used for the collective processing.
7. Other Embodiments
[0259] In other embodiments, time and frequency-domain analyses of IMP, PPG, PVP, and motion waveforms can be used to distinguish respiratory events such as coughing, wheezing, and to measure respiratory tidal volumes. In particular, respiratory tidal volumes are determined by integrating the area underneath a ‘respiratory pulse’ in an IMP or BR waveform (such as that indicated in
[0260] Other embodiments are within the scope of the invention. For example, other components of signals measured with the sensors within the IVDS, and particularly those used to measure PVP waveforms, can be analyzed to evaluate the patient.
[0261] In embodiments, for example, the arterial pulse pressure (herein “PP”) can be calculated from SYS and DIA as described above, and then analyzed to estimate a change in the patient's volume status, as less blood volume can lower arterial pulse pressure and more blood volume can raise arterial pulse pressure. Additionally, the venous system stores 60-70% of the blood volume and serves as a volume reservoir, and is a highly compliant, low-pressure system that can accommodate large changes in volume with minimal changes in pressure. The amplitude and shape of the PVP waveform has been demonstrated to be sensitive to changes in intravascular volume in recent studies. Changes in intravascular volume status in both humans and pigs led to changes in the PVP waveform before changes in arterial BP, HR, and the pulmonary artery diastolic pressure, suggesting that the PVP waveform is more sensitive to changes in intravascular volume than standard vital signs.
[0262] A venous segment's PVP waveform during a given cardiac cycle is the direct result of the blood volume changes that occur within that vein segment and the vein segment's compliance. The vein segment's compliance is expected to be constant during a given cardiac cycle and the corresponding compliance values over the duration of the cardiac cycle are determined by blood inflow and outflow for a given vein segment. Thus, the change in a vein segment's PVP during a given cardiac cycle is the result of the change in blood volume within the vein segment that occurs during a given cardiac cycle (i.e., the net effect on volume change resulting from blood flowing into and out of the vein segment). Based on the anatomical considerations and the results of the cited studies based on physiologic models, changes in PVP waveforms detected in a peripheral vein segment are due to net changes in the segment's blood volume over the course of each cardiac cycle.
[0263] Since the cyclical blood volume change (and corresponding cyclical pressure change) in a vein segment results from cardiac-induced cyclical change in flow into, and out of, the vein segment, the blood volume change in a vein segment results from the interaction of inflow pressure, outflow pressure, and intraluminal pressure. Thus, analysis of these parameters from the PVP waveform, as measured with the IVDS, may yield information concerning a patient's hemodynamic state.
[0264] When downstream resistance to venous return increases (for example, during atrial contraction or when the tricuspid valve closes), outflow pressure will increase. This causes a reduction (and eventual cessation once the proximal vein segment valve closes) of blood flow out of a given vein segment into the adjacent, downstream vein segment. Simultaneous, blood flow from the adjacent, upstream segment into the vein segment will continue but also decrease (and eventual cessation once the distal vein segment valve closes). The net effect of these two actions will increase the blood volume within the vein segment (where the PVP sensor is located) distending its walls outward and increasing intraluminal pressure (corresponding to the upstroke of the PVP waveform). Peak intraluminal pressure within the vein segment will occur just prior to the point when that pressure becomes greater than the outflow pressure.
[0265] In contrast, when downstream resistance to venous return decreases (for example, during atrial relaxation or when the tricuspid valve opens), outflow pressure will decrease. This causes an increase (and eventual cessation once the proximal vein segment valve closes) in blood flow out of a given vein segment into the adjacent, downstream vein segment. Simultaneous, blood flow out of the adjacent, upstream segment into the vein segment will begin to increase (and eventual cessation once the distal vein segment valve closes). The net effect of these two actions will decrease the blood volume within the vein segment (where the PVP sensor is located) allowing its walls to recoil and intraluminal pressure to decrease (corresponding to the downstroke of the PVP waveform). The vein segment intraluminal pressure nadir will occur just prior to the point when intraluminal pressure becomes less than the outflow pressure.
[0266] In summary, the PVP waveform measured from a vein segment is highly dependent on: i) the cycle of the right heart altering atrial volume and hence, atrial pressure, which in turn dictates venous return (i.e., venous outflow for a given peripheral vein segment; ii) blood flow out of the adjacent upstream vein segment into the adjacent downstream vein segment (i.e., venous inflow for a given peripheral vein segment); and iii) the compliance of the venous wall in that vein segment, which can be affected by changes in venous tone. All combined define the amplitude and shape of the PVP waveform.
[0267] Hypovolemia (e.g., blood loss, dehydration) has been shown to reduce the amplitude of PVP waveforms. Potential mechanisms for these findings include low arterial blood flow and blood pressure feeding the capillaries may lead to lower venous inflow and pressure, causing slower and/or reduced venous filling causing a more gradual upslope and/or lower peak venous pressure. Initially, hypovolemia may lower venous inflow (upstream) pressure more than venous outflow (downstream) pressure. This may lead to a more gradual downslope of the PVP waveform due to a reduced pressure gradient for blood flow out of the vein segment. Vasoconstriction in response to hypovolemia might exacerbate this effect if the vasoconstriction affects the arteries more than veins.
[0268] Lower venous inflow (upstream) pressure may also lead to a more gradual upslope of the PVP if the slower rate of venous filling does not allow the segment to reach maximum potential intraluminal pressure/distension before the right atrium either relaxes or the tricuspid valve opens allowing the downstream veins to start emptying.
[0269] As blood flows from the peripheral venous compartment to the central venous compartment falls, reduced downstream venous pressures can lower outflow pressure so that the maximum pressure change that can be achieved in the peripheral venous segment is reduced.
[0270] Even without changing the absolute blood volume, decreasing vasomotor tone simulates hypovolemia with some hemodynamic changes similar to those of absolute hypovolemia (e.g., reduced central pressures by reducing the stressed circulatory volume that generates venous return, reduced mean arterial pressure and potentially reduced cardiac output that can lead to reduced venous inflow pressure, and reduced venous intraluminal pressure). Lower venous tone also may lead to a more gradual upstroke and downstroke of the PVP waveform as more volume is required to increase the pressure in the vein segment when vessel diameter is increased. Similarly, increased venous tone can lead to the opposite effects—a steeper upstroke and downstroke of the vein segment PVP waveform.
[0271] In summary, PVP waveform's amplitude and shape primarily reflect changes in volume of the vein segment (where the PVP sensor is located) resulting from the interaction of blood inflow and blood outflow as the result of the changes in downstream or central venous volume/pressure changes driven by the cyclical contraction-relaxation of the right heart. The measured PVP waveform likely reflects the effective intravascular volume (the “stressed volume”, or the volume contributing to venous return and cardiac output) more closely than the absolute blood volume.
[0272] Other embodiments are within the scope of the invention. For example, signal-processing techniques outside (or in addition to) those described above can process PVP waveforms to isolate and improve the signal-to-noise ratio of PVP-AC and PVP-DC signal components, and particularly PVP-AC components. One such signal-processing technique is referred to as ‘wavelet decomposition’ and relates to the above-mentioned technique based on wavelet transforms. Wavelet decomposition algorithms approximate the PVP-AC signal with a collection of ‘wavelets’, each occurring at a different frequency (and usually octaves of each other). The algorithm only selects wavelets of certain, well-defined frequencies that are theoretically present in the desired signal, and then recombines these to approximate the PVP-AC signal. Wavelet decomposition can often yield reconstructed PVP-AC signals that indicate cardiac and respiratory pulses in a manner that is superior to conventional signal-processing techniques, such as infinite impulse response (herein ‘IIR’) filters commonly used in band-pass and low-pass filters. Additionally, wavelet decomposition is typically particularly effective in isolating PVP-AC pulses when pressure fluctuations due to pump activity, i.e. ‘pump noise’, is present and features similar frequency components compared to the PVP-AC signals.
[0273] In other embodiments, aimed at further increasing the signal-to-noise ratio of the PVP-AC signals, the tubing used to couple the venous catheter to the pressure transducer may be optimized. For example, the durometer (e.g., stiffness) of typically medical-grade tubing used in venous catheters is about 50-55 Shore A. Increasing this by roughly 25%, so that it is consistent with the durometer of tubing used for conventional arterial lines, increases the conductivity of high-frequency PVP-AC pulses so that they effectively and propagate in the tubing with minimal loss and are more readily detected. In related embodiments, the ‘fluid column’ within the tubing may be pressurized (e.g., using an external, pressurized IV bag filled with saline that is connected to the tubing), to further increase the tube's conductivity of the PVP-AC signals.
[0274] One purpose of analyzing PVP signals is to estimate a patient's volume status, and more specifically how the patient will respond to fluids. More specifically, it may be useful to determine where the patients ‘falls’ on the Frank-Starling curve, which plots stroke volume (e.g., flow) vs. pre-load (e.g., blood volume). A patient that is relatively ‘low’ on the curve will likely respond favorably to fluids, meaning their stroke volume may increase with increasing volume, which in turn is facilitated by increasing fluids. Conversely, a patient that is relatively ‘high’ on the curve may show little increase in flow when volume is increased. As such, an increased volume may drive the patient into a deleterious congestive state, such as congestive heart failure.
[0275] To this end, analysis of PVP-AC signals may yield a metric indicating how responsive the patient will be to infused fluids. This may include, for example, analysis of cardiac and respiratory components from the PVP-AC signals—wherein the signals are first processed using wavelet decomposition as described above—and then processing the resultant signals with an approach based on FFT or IIR filters to evaluate the relative magnitudes of both cardiac and respiratory components. Typically, for example, a patient will be responsive to fluids (e.g., their SV will subsequently increase) when the magnitude of the cardiac component is relatively small compared to the respiratory component. By using such data (typically collected during a clinical study) an embodiment of the invention may feature a simple ‘index’ that indicates the patient's responsivity to fluids. Such an index, for example, may be numerical (e.g., on a scale from 1-10), colorimetric (e.g., using ‘red’ to denote a patient in need of fluids; ‘green’ to denote a patient that is not in need of fluids), or something equivalent.
[0276] In still other embodiments, the index or other suitable metric for estimating the patient's fluid volume and/or responsivity may be based on the mean value of the PVP signal (herein “PVP-mean”), which is comparable to PVP-DC. PVP-mean indicates the mean pressure of the PVP signal. It has the advantage of always being present from the patient and relatively easy to process, mostly because it lacks oscillatory components related to the patient's cardiac or respiratory actions. Clinical work with the systems described herein indicates that that PVP-mean tracks a patient's receptivity to fluids when evaluated, for example, with lower body negative pressure (herein “LBNP”) clinical protocols. LBNP is an experimental maneuver that serves as a surrogate for hemorrhage—during LBNP, a subject's lower extremities are exposed to a systematically changing vacuum. This process pulls fluids from the subject's torso in a manner similar to hemorrhage. When the vacuum is released, blood and other fluids rush back into the subject's torso; this is analogous to transfusing blood back to a patient. Using the systems described herein, a surprising result of LBNP maneuvers applied to healthy subjects was that PVP-mean, along with the cardiac component of PVP-AC, systematically increased with increasing LBNP vacuum, and then rapidly returned to normal values once the vacuum was released. Thus, an index that includes PVP-mean by itself, or alternatively combined with components extracted from PVP-AC, can be used according to the invention to provide an index that indicates the patient's responsivity to fluids.
[0277] In yet another aspect of the invention, a ‘signal quality index’ (herein “SQI”) may be used with the above-described parameters (e.g. PVP-AC and the signal components therein; PVP-mean) to generate a comparable index. SQI is a metric that typically indicates the prevalence of a cardiac component in the PVP-AC signal: a low SQI indicates low amounts of a cardiac component, whereas a high SQI indicates high amounts of a cardiac component. Thus, low SQI values typically indicate a patient in need of fluids, whereas high SQI values typically indicate a patient with adequate fluids.
[0278] In still other embodiments of the invention, the PVP-monitoring components described herein may be coupled to other patient-worn sensors. For example, the patient may include a dressing or adhesive wrap that holds the venous catheter in place and simultaneously monitors the degree to which fluids or medication delivered by the IV ‘infiltrate’ out of the vein and into the 3rd space near the venous punction site. Signals measured by the dressing may be used to better process PVP-AC signals, as described herein. Conversely, the presence of PVP-AC signals indicate that a venous catheter is indeed properly in a patient's vein, and thus may be used with signals generated by the dressing to determine if fluids and/or medication delivered to the patient are infiltrating into their 3rd space.
[0279] These and other embodiments of the invention are deemed to be within the scope of the following claims.